These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Characteristic immunological responses to an experimental mouse brain tumor.
    Author: Yamasaki T, Handa H, Yamashita J, Namba Y, Hanaoka M.
    Journal: Cancer Res; 1983 Oct; 43(10):4610-7. PubMed ID: 6603902.
    Abstract:
    Immunological responses to an experimental brain tumor of mice [the 20-methylcholanthrene-induced malignant glioma, 203-glioma)] were investigated. The killer T-cell activity of spleen cells, which was specific against 203-glioma cells, began to be severely impaired 2 weeks after intracranial inoculation; this impairment was concurrent with increased intracranial pressure, which was due to developing tumor growth. On the other hand, the killer T-cell activity continued for over 4 weeks in mice inoculated with the mitomycin C-treated tumor cells. Surface marker analysis showed that Lyt-1-2,3+ killer T-cells were predominant in intracranial tumor-bearing mice, whereas both Lyt-1-,2,3+ and Lyt-1+,2,3+ killer T-cells were equally present in s.c. tumor-bearing mice. The effects of adult thymectomy on the immune responses against 203-glioma were also investigated in intracranial and s.c. tumor-bearing mice. In both the intracranially and s.c. inoculated groups, killer T-cell activity was increased in mice thymectomized before 3 weeks and decreased in mice thymectomized before 10 weeks. In these mice, Lyt-1+,2,3+ killer T-cells were not detected, which suggests strongly that the progenitors of Lyt-1+,2,3+ killer T-cells are short-lived lymphocytes in contrast to those of Lyt-1-,2,3+ killer T-cells, which survive more than 10 weeks after adult thymectomy.
    [Abstract] [Full Text] [Related] [New Search]